The continuing row over funding for Alzheimer's drugs on the NHS is set to go to the Court of Appeal.

Drugs company Eisai, which manufacturers one of the drugs - Aricept - is fighting a decision to restrict access to the drug to patients in the later stages of the disease.

Earlier this year, the High Court upheld a decision by the National Institute for Health and Clinical Excellence, which had concluded that the drugs are not cost-effective for patients in the early stages of Alzheimer's.

Topics